GlaxoSmithKline
Drug/indication: Dolutegravir, HIV
Approval decision date: Aug. 17

GlaxoSmithKline
Drug/indication: Trametenib, melanoma
Approval decision date: Sept. 3

Auxilium Pharmaceuticals ( AUXL)
Drug/indication: Xiaflex, Peyronie's Disease
Approval decision date: Sept. 6

Delcath Systems ( DCTH)
Drug/indication: Meblez, liver tumors due to ocular melanoma
Approval decision date: Sept. 13

Seattle Genetics ( SGEN)
Drug/indication: Adcetris, retreatment of Hodgkin's lymphoma
Approval decision date: Sept. 14

Antares Pharma ( ATRS)
Drug/indication: Otrexup, rheumatoid arthritis
Approval decision date: Oct. 14

Alimera Sciences ( ALIM), Psivida ( PSDV)
Drug/indication: Iluvien, diabetic macular edema
Approval decision date: Oct. 17

AMAG Pharmaceuticals ( AMAG)
Drug/indication: Feraheme, iron deficient anemia
Approval decision date: Oct. 21

Cubist Pharmaceuticals ( CBSST)
Drug/indication: Entereg, post-operative constipation
Approval decision date: Oct. 21

Gilead Sciences
Drug/indication: Sofosbuvir, hepatitis C
Approval decision date: Dec. 6

Amarin
Drug/indication: Vascepa, mixed dyslipidemia
Approval decision date: Dec. 20

Calendar compiled with assistance from BioMedTracker, company reports and TheStreet research.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Sarepta Therapeutics Chart Patterns Look Good

Verastem Shares Are Exploding 50% -- Here's Why

Watch the Key Technical Levels

Net Seller, but Itching to Put More Cash to Work